Microbiome and Premature Ovarian Insufficiency
Key facts
- Who runs it
- Westlake University
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 39 people enrolled
- Started
- 13 May 2025
- Ended
- 18 Dec 2025
- Type of study
- Observational, 2 groups
- Record updated
- 26 June 2026
Who can take part
- Age
- 20 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- (For POI patients)
- Women aged 20 to 40 years at screening visit
- Clinical diagnosis of premature ovarian insufficiency (based on diagnostic criteria: 25 < FSH ≤ 40 IU/L, reduced follicle count and abnormal follicle development by ultrasound)
- Able to provide informed consent; (For healthy volunteers)
- Age (±2 years) and sex-matched healthy control individuals for each POI patient
- Able to provide informed consent
Who cannot take part
- Use of hormone therapy (such as HRT) within the past 6 months
- Use of antibiotics in the past 3 months before sample collection
- Use of hormone therapy (e.g., loratadine, oral contraceptives, etc.) within the past 6 months
- Use of antibiotics in the past 3 months before sample collection
- Family history of premature ovarian insufficiency
- Serious illness (e.g., heart failure or malignancy)
- Smoking more than 15 cigarettes per day or history of alcohol or drug addiction
- Inflammatory gastrointestinal diseases
- Chronic diseases that may affect the gut microbiota (e.g., diabetes, cirrhosis, or cardiovascular disease)
- Blood or autoimmune diseases, or use of immunosuppressants in the past 3 months
- Have a history of infertility or recurrent miscarriage
- Inflammatory gastrointestinal diseases
- Smoking more than 15 cigarettes per day or history of alcohol or drug addiction
- Chronic diseases that may affect the gut microbiota (e.g., diabetes, cirrhosis, or cardiovascular disease)
- Blood or autoimmune diseases, or use of immunosuppressants in the past 3 months
- (For POI patients)
- Chronic constipation; (For healthy volunteers)
- Pregnant or breastfeeding
- Chronic constipation
- Participating in other clinical trials
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigates the differences in gut and vaginal microbiota between women with premature ovarian insufficiency (POI) and healthy volunteers. POI refers to the reduction in ovarian function before the age of 40, leading to irregular or absent menstruation and decreased estrogen levels, which can significantly affect women's reproductive and overall health. Recent research has suggested that gut microorganisms may influence the balance of steroid hormones through various metabolic pathways. Additionally, certain vaginal bacteria appear enriched in patients with POI, but whether these microorganisms directly impact ovarian function, and how, remains unclear. This study also seeks to address the underexplored role of fungi within the human microbiome. To comprehensively compare differences in gut and vaginal microbiota, the study will recruit 20 women with POI and 20 healthy controls. Both demographic and clinical information will be collected, along with biological samples including blood, urine, stool, and vaginal swabs.
The 2 groups in the trial
- POI
Premature ovarian insufficiency
- CTL
Healthy control
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Case-Control Study of Gut and Vaginal Microbiota Differences Between Premature Ovarian Insufficiency Patients and Healthy Controls
- Record updated
- 26 June 2026